1
|
A Novel Antibody Targeting the Second Extracellular Loop of the Serotonin 5-HT2A Receptor Inhibits Platelet Function. Int J Mol Sci 2022; 23:ijms23158794. [PMID: 35955928 PMCID: PMC9369033 DOI: 10.3390/ijms23158794] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 08/02/2022] [Accepted: 08/02/2022] [Indexed: 11/17/2022] Open
Abstract
Serotonin (5-hydroxytriptamine or 5-HT) is known to be a weak platelet agonist, and is involved in thrombus formation. While 5-HT cannot induce platelet aggregation on its own, when secreted from the alpha granules, it binds to its G-protein Coupled Receptor (GPCR; i.e., 5HT2AR), thereby acting to amplify platelet functional responses (e.g., aggregation). Thus, 5HT2AR-mediated responses are more involved in the secondary amplification of platelet aggregation in the growing thrombus. Therefore, even though 5-HT can be seen as a weak inducer of platelet activation, it is an important amplifier of aggregation triggered by agonists such as ADP, collagen, and epinephrine, thereby enhancing thrombogenesis. The 5HT2AR/5HT2A signaling pathway is of clinical interest to the scientific and medical communities as it has been implicated in the genesis of several forms of cardiovascular disorders. However, efforts to develop antagonists for 5HT2AR as therapeutic agents in cardiovascular diseases have thus far failed due to these reagents having deleterious side-effects, and/or to lack of selectivity, amongst other reasons. In light of research efforts that identified that the 5HT2AR ligand binding domain resides in the second extracellular loop (EL2; amino acids P209-N233), we developed an antibody, i.e., referred to as 5HT2ARAb, against the EL2 region, and characterized its pharmacological activity in the context of platelets. Thus, we utilized platelets from healthy human donors, as well as C57BL/6J mice (10-12 weeks old) to analyze the inhibitory effects of the 5HT2ARAb on platelet activation in vitro, ex vivo, and on thrombogenesis in vivo as well as on 5HT2AR ligand binding. Our results indicate that the 5HT2ARAb inhibits 5-HT-enhanced platelet activation in vitro and ex vivo, but has no apparent effects on that which is agonist-induced. The 5HT2ARAb was also found to prolong the thrombus occlusion time, and it did so without modulating the tail bleeding time, in mice unlike the P2Y12 antagonist clopidogrel and the 5HT2AR antagonist ketanserin. Moreover, it was found that the 5HT2ARAb does so by directly antagonizing the platelet 5HT2AR. Our findings document that the custom-made 5HT2ARAb exhibits platelet function blocking activity and protects against thrombogenesis without impairing normal hemostasis.
Collapse
|
2
|
Florez WA, García-Ballestas E, Maeda F, Joaquim A, Pavlov O, Moscote-Salazar LR, Tsimpas A, Martinez-Perez R. Relationship between aspirin use and subarachnoid hemorrhage: A systematic Review and meta-analysis. Clin Neurol Neurosurg 2020; 200:106320. [PMID: 33268193 DOI: 10.1016/j.clineuro.2020.106320] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 10/15/2020] [Accepted: 10/16/2020] [Indexed: 11/19/2022]
Abstract
BACKGROUND Aspirin has been associated with a decreasing risk of subarachnoid hemorrhage due to its anti-inflammatory mechanism of action and potential protective properties against aneurysm growth. OBJECTIVE To determine the association between aneurysmal subarachnoid hemorrhage and aspirin use. METHODS A systematic review of the literature and a meta-analysis were performed across the PubMed database. The following keywords were used: "aspirin, acetylsalicylic acid, 2-acetyloxy-benzoic acid, ruptured intracranial aneurysm, aneurysmal subarachnoid hemorrhage, spontaneous subarachnoid hemorrhage, intracerebral hemorrhage, spontaneous aneurysmal hemorrhage, spontaneous intracerebral bleeding". Studies that were performed with animals or analyzed patients with traumatic brain injury were excluded. A total of five studies were included in our meta-analysis, with a total of 19,222 patients evaluated. Statistical analysis was performed to determine the association between the use of aspirin and the risk of subarachnoid hemorrhage. RESULTS Aspirin use reduce the risk of subarachnoid hemorrhage (odds ratio [OR] 0.51, 95 % confidence interval [CI] 0.34-0.76). CONCLUSION Although some previous studies suggested that aspirin may potentially reduce the risk of subarachnoid hemorrhage, our meta-analysis found an association between the reduction of risk of aneurysmal subarachnoid hemorrhage.
Collapse
Affiliation(s)
- William A Florez
- Latinoamerican Council of Neurocritical Care, Cartagena, Colombia; Faculty of Health, Programa Medicina, Universidad Surcolombiana, Neiva, Huila, Colombia.
| | - Ezequiel García-Ballestas
- Latinoamerican Council of Neurocritical Care, Cartagena, Colombia; Centro De Investigaciones Biomédicas (CIB), Faculty of Medicine, University of Cartagena, Cartagena, Colombia
| | - Fernando Maeda
- Department of Neurosurgery, University of Campinas (UNICAMP), Sao Paulo, Brazil
| | - Andrei Joaquim
- Department of Neurosurgery, University of Campinas (UNICAMP), Sao Paulo, Brazil
| | - Orlin Pavlov
- Departament of Neurosurgery, Klinikum Fulda gAG, Fulda, Germany
| | - Luis Rafael Moscote-Salazar
- Latinoamerican Council of Neurocritical Care, Cartagena, Colombia; Centro De Investigaciones Biomédicas (CIB), Faculty of Medicine, University of Cartagena, Cartagena, Colombia
| | - Asterios Tsimpas
- Section of Neurosurgery, Department of Surgery, Advocate Illinois Masonic Medical Center, Chicago, IL, USA
| | | |
Collapse
|
3
|
Karim ZA, Vemana HP, Alshbool FZ, Lin OA, Alshehri AM, Javaherizadeh P, Paez Espinosa EV, Khasawneh FT. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Arterioscler Thromb Vasc Biol 2015; 35:637-44. [PMID: 25593131 DOI: 10.1161/atvbaha.114.304509] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
OBJECTIVE Platelet hyperactivity is associated with vascular disease and contributes to the genesis of thrombotic disorders. ADP plays an important role in platelet activation and activates platelets through 2 G-protein-coupled receptors, the Gq-coupled P2Y1 receptor (P2Y1R), and the Gi-coupled P2Y12 receptor. Although the involvement of the P2Y1R in thrombogenesis is well established, there are no antagonists that are currently available for clinical use. APPROACH AND RESULTS Our goal is to determine whether a novel antibody targeting the ligand-binding domain, ie, second extracellular loop (EL2) of the P2Y1R (EL2Ab) could inhibit platelet function and protect against thrombogenesis. Our results revealed that the EL2Ab does indeed inhibit ADP-induced platelet aggregation, in a dose-dependent manner. Furthermore, EL2Ab was found to inhibit integrin GPIIb-IIIa activation, dense and α granule secretion, and phosphatidylserine exposure. These inhibitory effects translated into protection against thrombus formation, as evident by a prolonged time for occlusion in a FeCl3-induced thrombosis model, but this was accompanied by a prolonged tail bleeding time. We also observed a dose-dependent displacement of the radiolabeled P2Y1R antagonist [(3)H]MRS2500 from its ligand-binding site by EL2Ab. CONCLUSIONS Collectively, our findings demonstrate that EL2Ab binds to and exhibits P2Y1R-dependent function-blocking activity in the context of platelets. These results add further evidence for a role of the P2Y1R in thrombosis and validate the concept that targeting it is a relevant alternative or complement to current antiplatelet strategies.
Collapse
Affiliation(s)
- Zubair A Karim
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Hari Priya Vemana
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Fatima Z Alshbool
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Olivia A Lin
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Abdullah M Alshehri
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Payam Javaherizadeh
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Enma V Paez Espinosa
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA
| | - Fadi T Khasawneh
- From the Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA.
| |
Collapse
|
4
|
The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation. Biochem Pharmacol 2012; 83:88-96. [DOI: 10.1016/j.bcp.2011.10.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Revised: 10/03/2011] [Accepted: 10/03/2011] [Indexed: 11/20/2022]
|
5
|
Affiliation(s)
- Carlos A Puyo
- Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| |
Collapse
|
6
|
Kasuya A, Holm K. Pharmacologic Approach to Ischemic Stroke Management. Nurs Clin North Am 1986. [DOI: 10.1016/s0029-6465(22)00417-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Bradley LM, Midgley FM, Watson DC, Getson PR, Scott LP. Anticoagulation therapy in children with mechanical prosthetic cardiac valves. Am J Cardiol 1985; 56:533-5. [PMID: 4036839 DOI: 10.1016/0002-9149(85)91179-8] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
From 1980 through 1984, 28 children younger than 19 years (mean 7.9) underwent cardiac valve replacement with 30 mechanical prostheses. Patients were followed for a total of 471 months (mean 15.7) and received either warfarin (mean 0.16 mg/kg/day) or acetylsalicylic acid and dipyridamole (mean 6.1 and 1.9 mg/kg/day, respectively) as thromboembolism prophylaxis. The frequency and incidence of thromboembolism and hemorrhage were compared. Warfarin-treated patients were at increased risk of hemorrhage (5 of 20 [25%], or 22 per 100 patient-years, vs 0 of 10 [0%], or 0 per 100 patient-years, p less than 0.05). Three of the 5 hemorrhagic episodes were mild, and in no case was hemorrhage life-threatening. Patients who did not receive warfarin had a greater risk of thromboembolism (2 of 10 [20%], or 12 per 100 patient-years, vs 0 of 20 [0%], or 0 per 100 patient-years, p less than 0.05). Both episodes of thromboembolism were life-threatening and necessitated emergency valve replacement. Although warfarin is associated with greater risk of hemorrhage than is acetylsalicylic acid and dipyridamole, warfarin is better than antiplatelet drugs in thromboembolism prophylaxis and is indicated for anticoagulation therapy in children with mechanical cardiac prostheses.
Collapse
|
8
|
Taomoto K, Asada M, Kanazawa Y, Matsumoto S. Usefulness of the measurement of plasma beta-thromboglobulin (beta-TG) in cerebrovascular disease. Stroke 1983; 14:518-24. [PMID: 6197783 DOI: 10.1161/01.str.14.4.518] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The plasma concentration of the platelet-specific protein beta-thromboglobulin (beta-TG) was measured in 39 normal subjects and 568 patients of neurological diseases. The beta-TG RIA commercially available KIT was also evaluated. Abnormally high plasma levels of beta-TG were demonstrated in groups of ischemic or obstructive cerebrovascular diseases as compared with that of normal subjects. The highest concentrations were found in 8 patients with Moya-Moya disease, (mean concentration of beta-TG was 204.4 ng/ml), completed stroke at an acute stage was next (mean beta-TG level was 194.8 +/- 70.8 ng/ml). On the other hand, many hemorrhagic cerebro-vascular diseases or other neurological diseases such as brain tumors, hydrocephalus, etc. do not show elevated beta-TG levels. In many patients with ischemic or obstructive cerebro-vascular diseases treated with anti-platelet drugs such as Aspirin, Dipyridamole, Bencyclane or Ticlopidine, a significant fall in plasma concentration of beta-TG was chronologically demonstrated. The measurement of plasma beta-TG concentration may be useful not only in the diagnosis of ischemic or obstructive cerebro-vascular disorders but also in judging the efficacy of anti-platelet therapies and prognosis.
Collapse
|
9
|
|
10
|
Abstract
Platelet aggregation generally is ordered by the physician to evaluate platelet function in hemorrhagic or thrombotic disorders. Malfunction of the platelet may be the result of an intrinsic congenital defect or an acquired problem induced by drugs or certain circulating plasma factors. It is necessary to obtain information from the patient with respect to family history, drug ingestion, physical or mental stress. In addition, other laboratory studies should be obtained to rule out general coagulation disorders affecting the plasma factors. A bleeding time will be helpful in establishing the severity of any platelet dysfunction. Technical considerations with regard to the preparation of the samples are of primary importance in determining platelet aggregation. Aggregating studies require the use of a variety of binding agents. (Studies on shape change, adhesion of platelets, release of platelet granule substance, and or lysis with extrusion of cytoplasmic constituents may be helpful in certain cases.) Instrumentation for platelet aggregation presently is available in many hospitals. The technical factors to be considered for routine aggregation studies include the type and strength of anticoagulant, centrifugation technique used in preparing the platelet-rich and platelet-poor plasma, platelet concentration, time of storage of the sample after venipuncture and after centrifugation, temperature, and the mixing of the sample. In general, critical concentrations of each reagent should be employed to improve the discrimination capability of the assay. Small differences in response may be obliterated by using excessive concentrations of a given reagent. Comparison in response to the test platelets with control platelets is best done at the same time by performing the aggregation in a dual instrument so that handling procedures will be identical and artifactual differences eliminated.
Collapse
|
11
|
Abstract
Seven patients with atrophie blanche or livedo vasculitis of the lower extremities showed abnormal platelet functions in vitro. Six of seven showed hyperaggregation with epinephrine and/or collagen, three showed increased platelet adhesiveness, three showed increased platelet count, and one showed increased microemboli. After treatment with dipyridamole and aspirin, all showed return to normal platelet function. Clinical improvement occurred in all patients, with significant alleviation of pain and decrease in new lesion formation. Although enhanced healing of lesions seemed evident to physician and patient, it was incomplete. In two patients, pain returned when dipyridamole and aspirin were stopped, but the patients improved again when the medicines were restarted. These preliminary findings indicate a possible beneficial effect of antiplatelet therapy in atrophie blanche and livedo vasculitis. A double-blind study is being undertaken to further study this effect.
Collapse
|
12
|
DeAmbroggi L, Barbieri P, DeBiase AM, Repetto S, Radice M. Assessment of diagnostic value of dipyridamole testing in angina pectoris. Clin Cardiol 1982; 5:269-74. [PMID: 7083650 DOI: 10.1002/clc.4960050402] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
In order to assess the diagnostic value of dipyridamole (D) testing, we studied the responses of 34 patients with chest pain and 10 normal subjects. Blood pressure and 12-lead ECG were recorded during and after intravenous infusion of 0.6 mg/kg dipyridamole for 10 minutes. Coronary arteriography and maximal or symptom-limited exercise tests were performed in the 34 patients with chest pain. During infusion 13 patients presented ischemic ST changes and 5 with anginal pain only. The latter group had normal coronary arteries. Among the 13 patients with ischemic ST changes, 7 had at least two critical coronary stenoses and the remaining 6 had no coronary lesions. Dipyridamole tests showed poor sensitivity (44%) and specificity (39%) with respect to coronary arteriography. The relatively high number of positive responses in subjects with normal coronary arteries indicates that the coronary steal phenomenon is not the sole cause of "ischemic" response to the drug. Indirect indexes of myocardial oxygen consumption were higher in patients with a positive response to drug infusion than in those with a negative response; however the value of rate-pressure product at infusion end never reached that observed at ischemic threshold during exercise testing in the same patient. This suggests that neither can oxygen consumption increase be considered as entirely responsible for ischemic response to dipyridamole. In conclusion dipyridamole test cannot be proposed for predicting critical coronary stenoses.
Collapse
|
13
|
ROBINS GM, WILKINSON GT, MENRATH VH, ATWELL RB, RIESZ G. Long-term survival following embolectomy in two cats with aortic embolism. J Small Anim Pract 1982. [DOI: 10.1111/j.1748-5827.1982.tb01654.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
14
|
Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981; 48:395-402. [PMID: 6168192 DOI: 10.1016/0002-9149(81)90065-5] [Citation(s) in RCA: 117] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
15
|
Abstract
The effect of sulfinpyrazone (Anturane) on the extent of myocardial lesions caused by coronary ligation or isoproterenol, 5 mg/kg subcutaneously, was determined in the rat. Treatment was with sulfinpyrazone, 15 mg/kg twice daily for 5 days before the cardiac insult, or 21 days after the insult, or both. Pretreatment with sulfinpyrazone reduced isoproterenol-induced lesions by 42%. Treatment after isoproterenol had no significant effect. With coronary ligation, treatment before or after operation significantly reduced the size of infarct, pretreatment by 42%, post-treatment by 33%. The results provide evidence that sulfinpyrazone may have a clinically useful protective effect in individuals at risk of cardiac ischemia, as suggested in the Anturane Reinfarction Trial.
Collapse
|
16
|
Moschos CB, Escobinas AJ, Jorgensen OB, Regan TJ. Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. Circulation 1981; 64:13-8. [PMID: 7237710 DOI: 10.1161/01.cir.64.1.13] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
In patients treated with sulfinpyrazone, an apparent reduction in the incidence of sudden death and presumed ventricular fibrillation has been reported. Using an intact animal model without microcirculatory thrombosis, we studied the effects of sulfinpyrazone on ischemic myocardium in 58 anesthetized dogs divided into three groups: control untreated (n =24), group 1 (n = 16), treated daily with 300 mg of sulfinpyrazone for 7 days, and group 2 (n = 18), treated daily with 300 mg of sulfinpyrazone for 7 days but omitting treatment on day 8. Although consistent hemodynamic differences were not apparent, the degree of injury determined by ECG mapping was significantly lower in group 1. The incidence of fibrillation was 54% for control and 0% in group 1. Group 2 had a 44% incidence, suggesting a limited duration of action. The apparent absence of microcirculatory thrombosis in this model suggests other mechanisms of action. A significantly smaller increase in tissue water and Na+ and smaller loss of K+ in group 1 may have contributed to the lower incidence of fibrillation, perhaps through selective prostaglandin inhibition.
Collapse
|
17
|
Viinikka L, Ylikorkala O. Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Br J Pharmacol 1981; 72:299-303. [PMID: 7011467 PMCID: PMC2071515 DOI: 10.1111/j.1476-5381.1981.tb09129.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
1 Thirty-six healthy human subjects were randomly divided into six groups which were treated with a single dose of 75 mg (1.3 mg/kg) of dipyridamole alone, or 75 mg of dipyridamole in combination with 30 mg (0.5 mg/kg), 50 mg (0.8 mg/kg), 160 mg (2.6 mg/kg) and 330 mg (5.7 mg/kg) of acetylsalicylic acid (ASA), or with placebo. 2 The concentrations of prostacyclin (PGI2) and thromboxane A2 (TxA2) metabolites, 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and TxB2 respectively, were measured in serum with specific radioimmunoassays before and 1 and 3 h afer the ingestion of the test dose. 3 The basal concentrations of 6-keto-PGF1 alpha and TxB2 correlated significantly (r = 0.588, P less than 0.001). 4 Dipyridamole alone did not change PGI2 or TxA2 production. 5 Dipyridamole-ASA combinations with ASA doses between 0.5 and 0.8 mg/kg inhibited TxB2 production by 48 to 74% and with the ASA doses between 2.6 and 5.7 mg/kg by about 90%. None of these combinations changed PGI2 production. 6 The ratio of 6-keto-PGF1 alpha to TxB2 increased 3.5 to 6 times with ASA doses of 0.5 to 0.8 mg/kg and 21 to 29 times with doses between 2.6 to 5.7 mg/kg. 7 These results suggest that the anti-thrombotic effect of dipyridamole in vivo is not mediated through direct changes in PGI2 and/or TxA2 production.
Collapse
|
18
|
Abstract
Management of patients with sudden neurological deficit must be based on complete knowledge of the underlying cause. In about 80% of such patients, a careful history and examination will lead to a precise etiologic and anatomic diagnosis. If the deficit is vascular in etiology, therapy and prognosis depend on its stage of evolution.
Collapse
|
19
|
Kohler C, Tolman E, Wooding W, Ellenbogen L. Fenbufen and biphenylacetic acid inhibit platelet function and the arachidonate prostaglandin system. Thromb Res 1980; 20:123-35. [PMID: 6782695 DOI: 10.1016/0049-3848(80)90062-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
20
|
Pirk J, Ruzbarský V, König J, Krajícek M, Pavel P, Firt P. The effect of antiaggregating drugs on the patency of grafts in the arterial system. World J Surg 1980; 4:615-9. [PMID: 6894509 DOI: 10.1007/bf02401646] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
21
|
|
22
|
Pfister B, Godbillon J, Colussi D, Imhof P. Effect of orally administered sulphinpyrazone (Anturan) on platelet aggregation in vitro. Thromb Res 1980; 18:89-99. [PMID: 7404507 DOI: 10.1016/0049-3848(80)90173-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
23
|
|
24
|
Atkinson DC, Collier HO. Salicylates: molecular mechanism of therapeutic action. ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY 1980; 17:233-88. [PMID: 7004141 DOI: 10.1016/s1054-3589(08)60012-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
25
|
Fuccella LM. Clinical pharmacology of inhibitors of platelet aggregation. PHARMACOLOGICAL RESEARCH COMMUNICATIONS 1979; 11:825-52. [PMID: 395541 DOI: 10.1016/s0031-6989(79)80010-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
26
|
Rajah SM, Penny AF, Crow MJ, Pepper MD, Watson DA. The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time. Br J Clin Pharmacol 1979; 8:483-9. [PMID: 508556 PMCID: PMC1429809 DOI: 10.1111/j.1365-2125.1979.tb01031.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
1 In normal volunteers maximum reductions in platelet functions, collagen aggregation, adhesion and PF4 availability, were achieved using combined doses of 50 mg three times daily dipyridamole + 180 mg ASA or 75 mg three times daily dipyridamole + 120 mg ASA daily. 2 These doses did not prolong the bleeding time. 3 A synergistic effect has been demonstrated with 25 mg dipyridamole three times daily and 60 mg ASA. 4 At higher doses the effects on platelet functions were additive up to the maximal response. 5 The effect of low doses of ASA on platelet function was cumulative. 6 As lower doses of ASA in the combination studied inhibit platelet functions maximally without altering the bleeding time and probably without inhibiting prostacyclin, we suggest that these combinations of dipyridamole and ASA merit consideration in future clinical trials.
Collapse
|
27
|
|
28
|
Gaynor BJ, Constantine JW. The effect of piroxicam on platelet aggregation. EXPERIENTIA 1979; 35:797-8. [PMID: 467595 DOI: 10.1007/bf01968256] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Piroxicam inhibited aggregation of human and dog platelets caused by collagen, but not by adenosine diphosphate (ADP). Release of platelet ADP was inhibited by piroxicam.
Collapse
|
29
|
Gertz SD, Kurgan A, Wajnberg RS, Nelson E. Endothelial cell damage and thrombus formation following temporary arterial occlusion. Effects of pretreatment with aspirin or heparin. J Neurosurg 1979; 50:578-86. [PMID: 430151 DOI: 10.3171/jns.1979.50.5.0578] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
✓ The effects of restoration of blood flow on endothelial damage that occurs distal to the site of temporary arterial occlusion with surgical clips, and the effects of heparin and aspirin on thrombus formation at the site of the clip, were studied by scanning electron microscopy (SEM). The right carotid artery of 45 rabbits was occluded with a Heifetz clip for 30 minutes. The clips were then removed and blood flow resumed for periods of 30 minutes, 1 hour, 2 hours, and 24 hours. A second group was preteated intravenously with heparin (1400 units/kg), and a third group was pretreated orally with aspirin (50 mg/kg). The SEM analysis of arterial segments distal and proximal to the clip indicated that the frequency of occurrence of endothelial crater- and balloon-like vesicular defects decreased to zero within 24 hours of restoration of blood flow. Examination of arterial segments compressed by the clip revealed endothelial desquamation and thrombus formation within 30 minutes of resumption of flow. The maximum degree of thrombus formation occurred within 1 to 2 hours of resumption of flow, with a subsequent decrease in the extent of deposition of platelets, fibrin, erythrocytes, and leukocytes within 24 hours. No change was found in composition or quantity of thrombus formation after pretreatment with heparin although, in the latter specimens, fibrin deposition appeared considerably less. However, pretreatment with aspirin resulted in marked reduction in the overall quantity of thrombus formation at the site of the clip following temporary occlusion.
Collapse
|
30
|
|
31
|
Bergamaschi M, Ceserani R, Pierucci L, Pogliani E, Spelta A. Indobufen, a new inhibitor of platelet aggregation. Studies in guinea pigs. PHARMACOLOGICAL RESEARCH COMMUNICATIONS 1979; 11:279-94. [PMID: 461494 DOI: 10.1016/s0031-6989(79)80090-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
32
|
Abstract
Efforts have been made to develop noncorticosteroidal anti-inflammatory therapy. The goals of such therapy have been to eradicate the primary cause, prevent the initial tissue injury, moderate inflammatory response, and enhance tissue repair while minimizing and eliminating the undesirable aspects of the therapy.
Collapse
|
33
|
Wiley JS, Chesterman CN, Morgan FJ, Castaldi PA. The effect of sulphinpyrazone on the aggregation and release reactions of human platelets. Thromb Res 1979; 14:23-33. [PMID: 570742 DOI: 10.1016/0049-3848(79)90021-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
34
|
|
35
|
Salzman EW. Influence of antiplatelet drugs on platelet-surface interactions. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1978; 102:265-83. [PMID: 685754 DOI: 10.1007/978-1-4757-1217-9_18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Platelet aggregates are important in the thromboembolic complications of prosthetic devices, and drugs that alter platelet function have shown promise in clinical trials. Results with these drugs have increased insight into the interaction of platelets with artificial materials, particularly when the clinical experience has been correlated with the results of in vitro models. In a bead column/surface contact model, the characteristic interactions of platelets with artificial surfaces resemble effects of adding thrombin ADP to platelet-rich plasma. Anti-inflammatory agents and other antiplatelet drugs inhibit these reactions. Results in an in vivo model, survival of 51 Cr-labeled platelets in sheep bearing arteriovenous shunts of test materials, correlate systems indicate that the initial events upon contact of a surface with plasma proteins persistently influence the long-term behavior of that surface toward blood. A review of clinical studies discusses the effect of antiplatelet drugs on platelet survival and also on thrombotic complications of heart valve replacement and other conditions employing prosthetic devices.
Collapse
|
36
|
|
37
|
DiPasquale G, Mellace D. Inhibition of arachidonic acid induced mortality in rabbits with several non-steroidal anti-inflammatory agents. AGENTS AND ACTIONS 1977; 7:481-5. [PMID: 930759 DOI: 10.1007/bf01966857] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The intravenous administration of arachidonic acid to rabbits is an effective in vivo model for evaluating potential anti-thrombotic drugs. Most of the non-steroidal anti-inflammatory agents (NSAIFA) inhibit this arachidonic acid induced mortality (except sodium salicylate and acetaminophen). However, there is a lack of correlation between the relative potencies from various assays (rabbit anti-thrombotic, anti-inflammatory, alalgesic, ulcerogenic and inhibition of prostaglandin synthetase evaluations). These studies imply other actions with NSAIFA than an effect solely on the prostaglandin biosynthetic pathway.
Collapse
|
38
|
Fulton WF, Summer DJ. The great circulatory paradox. Lancet 1977; 2:46. [PMID: 69138 DOI: 10.1016/s0140-6736(77)90051-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
39
|
|
40
|
Tilley LP, Weitz J. Pharmacologic and other forms of medical therapy in feline cardiac disease. THE VETERINARY CLINICS OF NORTH AMERICA 1977; 7:415-28. [PMID: 325874 DOI: 10.1016/s0091-0279(77)50039-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
41
|
Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT. INTERACTION OF PLATELETS WITH SUBENDOTHELIUM: A NEW METHOD FOR IDENTIFYING AND CLASSIFYING ABNORMALITIES OF PLATELET FUNCTION. Ann N Y Acad Sci 1977. [DOI: 10.1111/j.1749-6632.1977.tb41776.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|